(Q40527756)

21 September 2017

title

Aripiprazole, a novel atypical antipsychotic drug (English)

1 reference

21 September 2017

2

1 reference

21 September 2017

Tami R Argo

1

1 reference

21 September 2017

Paul J Perry

series ordinal

3

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

24

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

212-228

1 reference

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Dopamine agonists in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Serotonin-dopamine interaction and its relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

Pramipexole as adjunct to haloperidol in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.2.212.33145

10.1592/PHCO.24.2.212.33145

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference